S'abonner

Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States - 29/06/13

Doi : 10.1016/j.ahj.2013.03.016 
Meredith C. Foster, ScD, MPH a, Andreea M. Rawlings, MS a, Elizabeth Marrett, MPH b, David Neff, DO b, Kerry Willis, PhD c, Lesley A. Inker, MD, MS d, Josef Coresh, MD, PhD a, e, f, Elizabeth Selvin, PhD, MPH a, f,
a Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health and Medical Institutions, Baltimore, MD 
b Merck, Sharp & Dohme Corp., Whitehouse Station, NJ 
c National Kidney Foundation, New York, NY 
d Division of Nephrology, Tufts Medical Center, Boston, MA 
e Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
f Department of Medicine, Johns Hopkins Hospital, Baltimore, MD 

Reprint requests: Elizabeth Selvin, PhD, MPH, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Suite 2-600, Baltimore MD 21287.

Résumé

Background

Cardiovascular disease is a major concern in persons with chronic kidney disease (CKD). We assessed the current burden of cardiovascular risk factors and differences in risk factor treatment and control in the general US adult population by CKD status.

Methods

A cross-sectional study of 10,741 adults aged 20+ years from the 2007-2010 National Health and Nutrition Examination Survey was performed. Persons were categorized into 3 groups: CKD stages 3 to 5 (estimated glomerular filtration rate <60 mL/min/1.73 m2), CKD stages 1 and 2 (urinary albumin-to-creatinine ratio ≥30 mg/g and estimated glomerular filtration rate ≥60 mL/min/1.73 m2), and no CKD.

Results

The majority of adults with CKD stages 3 to 5 (79.8%) and stages 1 and 2 (59.1%) had ≥2 cardiovascular risk factors, substantially higher than adults without CKD (32.7%, P < .001). Diabetes was the most strongly associated risk factor and was highly specific for CKD stages 1 and 2 (prevalence ratio 2.53, 95% CI 2.21-2.89) and, to a lesser extent, CKD stages 3 to 5 (prevalence ratio 1.59, 95% CI 1.38-1.84). Most adults with diagnosed risk factors reported medication use for risk factor control, and pharmacologic treatment was more common among those with than without CKD. However, poor risk factor control was also common among persons treated for risk factors with CKD compared with those without CKD.

Conclusions

There continues to be a substantial cardiovascular risk factor burden among adults with CKD stages 3 to 5 and, to a lesser extent, adults with CKD stages 1 and 2 when compared with adults without CKD. Overall, optimal risk factor control is low in adults with CKD, highlighting the need for aggressive cardiovascular risk reduction in adults with CKD.

Le texte complet de cet article est disponible en PDF.

Plan


 Funding acknowledgement: This study was supported by the National Kidney Foundation (grant to Johns Hopkins) and Merck Sharp and Dohme Corp, a subsidiary of Merck & Co, Inc, Whitehouse Station, NJ (professional service agreement to the National Kidney Foundation). D.N. and E.M. are employees of Merck and own stock in the company. M.C.F. is supported by a National Institutes of Health/National Heart, Lung, and Blood Institute T32HL007024 Cardiovascular Epidemiology Training Grant. The National Health and Nutrition Examination Survey is funded by the National Center for Health Statistics, Centers for Disease Control and Prevention, Department of Health and Human Services.


© 2013  Mosby, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 166 - N° 1

P. 150 - juillet 2013 Retour au numéro
Article précédent Article précédent
  • Renal dysfunction and long-term risk of heart failure after coronary artery bypass grafting
  • Martin J. Holzmann, Carl Gardell, Anders Jeppsson, Ulrik Sartipy
| Article suivant Article suivant
  • Educational Videos to Reduce Racial Disparities in ICD therapy Via Innovative Designs (VIVID): A randomized clinical trial
  • Kevin L. Thomas, Louise O. Zimmer, David Dai, Sana M. Al-Khatib, Nancy M. Allen LaPointe, Eric D. Peterson

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.